February 11, 2019 08:35 AM EST
Pharma

Ab­b­Vie jumps in­to the fren­zied race for a BC­MA/CD3 bis­pe­cif­ic tar­get­ing mul­ti­ple myelo­ma. Teneo­bio who?

John Carroll

Editor & Founder

Every­body wants a BC­MA bis­pe­cif­ic. And Ab­b­Vie just front­ed $90 mil­lion to get one from a lit­tle-known Sil­i­con Val­ley biotech called Teneo­bio.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times